247 related articles for article (PubMed ID: 2974309)
1. Malignancy-associated hypercalcaemia: relationship between mechanisms of hypercalcaemia and response to antihypercalcaemic therapy.
Ralston SH; Gardner MD; Jenkins AS; McKillop JH; Boyle IT
Bone Miner; 1987 May; 2(3):227-42. PubMed ID: 2974309
[TBL] [Abstract][Full Text] [Related]
2. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
[TBL] [Abstract][Full Text] [Related]
3. Hypercalcaemia and breast cancer--an increased humoral component in patients with liver metastases.
Coleman RE; Fogelman I; Rubens RD
Eur J Surg Oncol; 1988 Oct; 14(5):423-8. PubMed ID: 2846366
[TBL] [Abstract][Full Text] [Related]
4. Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.
Weissglas M; Löwik C; Schamhart D; Theuns H; Kurth KH; Papapoulos S
BJU Int; 2007 Jun; 99(6):1530-3. PubMed ID: 17428243
[TBL] [Abstract][Full Text] [Related]
5. Humoral hypercalcaemia of malignancy: metabolic and histomorphometric studies during surgical management of the primary tumour.
Ralston SH; Boyce BF; Cowan RA; Gardner MD; Dryburgh FJ; Boyle IT
Q J Med; 1986 Mar; 58(227):325-35. PubMed ID: 3016790
[TBL] [Abstract][Full Text] [Related]
6. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
[TBL] [Abstract][Full Text] [Related]
7. Familial benign hypercalcaemia. Study of a large family.
Menko FH; Bijvoet OL; Fronen JL; Sandler LM; Adami S; O'Riordan JL; Schopman W; Heynen G
Q J Med; 1983; 52(206):120-40. PubMed ID: 6310672
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcaemia due to malignancy. Role of the kidney and treatment.
Sleeboom HP; Bijvoet OL
Contrib Nephrol; 1982; 33():178-96. PubMed ID: 6214375
[No Abstract] [Full Text] [Related]
9. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
Ralston SH; Alzaid AA; Gardner MD; Boyle IT
Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
[TBL] [Abstract][Full Text] [Related]
10. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
Clines GA; Guise TA
Endocr Relat Cancer; 2005 Sep; 12(3):549-83. PubMed ID: 16172192
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy.
Hosking DJ; Gilson D
Q J Med; 1984; 53(211):359-68. PubMed ID: 6484118
[TBL] [Abstract][Full Text] [Related]
12. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
13. Calcium metabolism and hyperparathyroidism after renal transplantation.
Cundy T; Kanis JA; Heynen G; Morris PJ; Oliver DO
Q J Med; 1983; 52(205):67-78. PubMed ID: 6348830
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis and management of cancer associated hypercalcaemia.
Ralston SH
Cancer Surv; 1994; 21():179-96. PubMed ID: 8564993
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology and management of severe hypercalcemia.
Nussbaum SR
Endocrinol Metab Clin North Am; 1993 Jun; 22(2):343-62. PubMed ID: 8325291
[TBL] [Abstract][Full Text] [Related]
16. [Palliative therapy in cancer. 4. Palliation of the symptoms from a malignant tumor. (2)].
Urushizaki I
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1525-35. PubMed ID: 1697156
[TBL] [Abstract][Full Text] [Related]
17. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.
Ralston SH; Fogelman I; Gardiner MD; Boyle IT
Br Med J (Clin Res Ed); 1984 May; 288(6428):1405-8. PubMed ID: 6426577
[TBL] [Abstract][Full Text] [Related]
18. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
19. Treatment of malignant hypercalcaemia.
Hurtado J; Esbrit P
Expert Opin Pharmacother; 2002 May; 3(5):521-7. PubMed ID: 11996631
[TBL] [Abstract][Full Text] [Related]
20. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
